Eli Lilly and Co on Tuesday said it and partner Pfizer Inc aim to seek approval by 2018 for a new type of pain drug that could be an alternative to opioids for osteoarthritis, chronic back pain and cancer pain. The Indianapolis drugmaker said tanezumab, given by injection every eight weeks, could be a far more effective and appropriate alternative for chronic pain than opioids, without their abuse potential.
More here:
Lilly says new type of pain drug could lessen need for opioids
